Literature DB >> 19786666

Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.

Aliki J Taylor1, Clare Frobisher, David W Ellison, Raoul C Reulen, David L Winter, Roger E Taylor, Charles A Stiller, Emma R Lancashire, Edward C G Tudor, Christina Baggott, Shaun May, Mike M Hawkins.   

Abstract

PURPOSE: Survival after brain or spinal cord neoplasms is poor and varies by diagnostic group, age, grade, treatment and pretreatment factors, and location and size of tumor. We carried out a study to investigate survival and factors affecting survival of all diagnostic types of second primary brain or spinal cord neoplasms. PATIENTS AND METHODS: The British Childhood Cancer Survivor Study (BCCSS) is a long-term population-based follow-up study of 17,980 5-year survivors of childhood cancer. We used relative survival and multivariate Cox regression analysis to determine 5-year relative survival and factors affecting survival in second primary meningiomas and gliomas that developed in survivors included in the BCCSS.
RESULTS: There were 247 second primary brain or spinal cord neoplasms, including 137 meningiomas and 73 gliomas in a young adult population. Five-year relative survival after meningiomas was similar for males (84.0%; 95% CI, 72.6% to 91.1%) and females (81.7%; 95% CI, 69.9% to 89.3%). For gliomas, 5-year relative survival was 19.5% (95% CI, 8.6% to 33.7%) for males and females. Multivariate analysis showed significant heterogeneity by decade of treatment (P = .04), grade (P = .03), and genetic risk (P = .03) for rate of mortality after a meningioma. For gliomas, survival was significantly affected by grade (P < .001).
CONCLUSION: Our results indicate survival is poor after second primary glioma in this young adult population, although survival after second primary meningioma is good. Our study has clinical implications for the surveillance of childhood cancer survivors at risk of developing second primary brain tumors, in particular survivors of childhood acute lymphoblastic leukemia or childhood brain tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19786666     DOI: 10.1200/JCO.2009.22.4386

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.

Authors:  Aliki J Taylor; Mark P Little; David L Winter; Elaine Sugden; David W Ellison; Charles A Stiller; Marilyn Stovall; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Michael M Hawkins
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort).

Authors:  Julie Berbis; Gérard Michel; André Baruchel; Yves Bertrand; Pascal Chastagner; François Demeocq; Justyna Kanold; Guy Leverger; Dominique Plantaz; Marilyne Poirée; Jean-Louis Stephan; Pascal Auquier; Audrey Contet; Jean-Hugues Dalle; Stéphane Ducassou; Virginie Gandemer; Patrick Lutz; Nicolas Sirvent; Marie-Dominique Tabone; Sandrine Thouvenin-Doulet
Journal:  Int J Epidemiol       Date:  2014-03-17       Impact factor: 7.196

3.  Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study.

Authors:  Daniel C Bowers; Chaya S Moskowitz; Joanne F Chou; Claire M Mazewski; Joseph P Neglia; Gregory T Armstrong; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2017-03-24       Impact factor: 44.544

4.  Risk of Second Primary Neoplasms of the Central Nervous System.

Authors:  Elisa K Liu; Cheongeun Oh; Douglas Kondziolka; Erik P Sulman
Journal:  Adv Radiat Oncol       Date:  2022-04-18

Review 5.  Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review.

Authors:  Daniel C Bowers; Paul C Nathan; Louis Constine; Catherine Woodman; Smita Bhatia; Karen Keller; Lisa Bashore
Journal:  Lancet Oncol       Date:  2013-07       Impact factor: 41.316

6.  Resveratrol Inhibits Proliferation in HBL-52 Meningioma Cells.

Authors:  Shun-An Hu; Wei Wei; Jia Yuan; Jin Cheng
Journal:  Onco Targets Ther       Date:  2019-12-30       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.